ストックスクリーナーアプリを入手
12.19
1.46%
-0.18
アフターアワーズ：
12.03
-0.16
-1.31%
Cogent Biosciences Inc (COGT) 最新ニュース
Is Cogent Biosciences Inc. stock overhyped or has real potentialExplosive capital appreciation - jammulinksnews.com
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen - Insider Monkey
What analysts say about Cogent Biosciences Inc. stockPhenomenal capital appreciation - jammulinksnews.com
What drives Cogent Biosciences Inc. stock priceExceptional trading performance - Autocar Professional
2 Biotech and 2 Tech Stocks Insiders Are Scooping Up Now - 24/7 Wall St.
Is Cogent Biosciences Inc. a good long term investmentMarket-beating performance - jammulinksnews.com
Cogent Biosciences Inc. Stock Analysis and ForecastGame-changing returns - jammulinksnews.com
Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $22 - 富途牛牛
Cogent Biosciences (NASDAQ:COGT) Given New $22.00 Price Target at Citigroup - MarketBeat
3 Stocks With Sky-High Overbought Signals: QuantumScape, Opendoor, Cogent Flash RSI Red Flags - Benzinga
When (COGT) Moves Investors should Listen - news.stocktradersdaily.com
Cogent Biosciences (COGT) Target Price Raised by Citigroup | COG - GuruFocus
Cogent Biosciences stock hits 52-week high at 12.66 USD By Investing.com - Investing.com South Africa
Cogent Biosciences stock hits 52-week high at 12.66 USD - Investing.com
Blueprint Medicines' (BPMC) Ayvakit Faces Competition from Cogent Biosciences | BPMC Stock News - GuruFocus
Blueprint Medicines' (BPMC) Ayvakit Faces Competition from Cogen - GuruFocus
Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating - MSN
Cogent Biosciences: Analyst Maintains Buy Rating Amid Promising Trials and Strategic Advantages - AInvest
Day 11 of Gains Streak for Cogent Biosciences Stock with 67% Return (vs. 52% YTD) [7/16/2025] - Trefis
10 Best Small-Cap Stocks to Buy According to Billionaires - Insider Monkey
COGT Stock Up 62% after 10-Day Win Streak - Trefis
Mintz Advises on Cogent Biosciences’ $230 Million Public Offering - Mintz
Press Release: Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock - 富途牛牛
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - MSN
Cogent Biosciences (NASDAQ:COGT) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - MarketBeat
Guggenheim Reiterates "Buy" Rating for Cogent Biosciences with $17 Price Target - AInvest
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $22.00 at HC Wainwright - MarketBeat
Cogent Biosciences Closes $230 Million Upsized Stock Offering - MarketScreener
Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Cogent Biosciences Announces Closing of Upsized Public - GlobeNewswire
Cogent Biosciences Secures Massive $230M Funding for Bezuclastinib Drug Development - Stock Titan
Cogent Biosciences’ Mysterious 5.6% Surge: What’s Behind the Move? - AInvest
Cogent Biosciences' 8% Surge: Unraveling the Mystery Behind the Spike - AInvest
Cogent Biosciences(COGT) Soars 6.34% on Phase III Success - AInvest
Form 424B5 Cogent Biosciences, Inc. - StreetInsider
Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results (COGT) - Seeking Alpha
Cogent Biosciences: Drug Trial Triumph Sparks Stock Surge - StocksToTrade
A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $17 to $25 - 富途牛牛
Cogent Biosciences slips after upsized $200 mln equity offering - TradingView
Cogent Biosciences Prices $200 Million Stock Offering - MarketScreener
Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock - The Manila Times
Cogent Biosciences (COGT) Prices $200M Public Offering at $9 Per Share - GuruFocus
Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges - NewsBreak: Local News & Alerts
3.32%
1.57%
大文字化:
|
ボリューム (24 時間):